Laser Acupuncture on Irritable Bowel Syndrome in Females
- Conditions
- Constipation-predominant Irritable Bowel Syndrome
- Registration Number
- NCT05757037
- Lead Sponsor
- Cairo University
- Brief Summary
The aim of the study to investigate effect of laser acupuncture on constipation predominant irritable bowel syndrome in female patients
- Detailed Description
Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and/or bloating related to defecation without reliable biological markers . IBS is associated with substantial burden, such as higher levels of anxiety, lost productivity at work, work absenteeism (Pimentel, 2018). IBS has a strong predominance in women IBS-C includes a wide range of symptoms, and its pathophysiology is complex and not fully understood. Visceral hypersensitivity and delayed gut transit are recognized as major pathophysiological mechanisms in IBS-C. Visceral hypersensitivity may account for symptoms of abdominal pain, bloating, and discomfort. Delayed gut transit causes constipation The unsatisfactory treatment responses and adverse effects associated with pharmacologic therapies have resulted in a higher demand for alternative therapies Acupoints and manipulations are the same in both the experimental and the control groups. The participants in the control group will receive sham laser acupuncture treatment, without any laser output, while the participants in the experimental group will sequentially receive 0.375J of energy at each of the following acupoints: Baihui (GV20), Yintang (GV29), Taichong (LR3), Zusanli (ST36), Sanyinjiao (SP6), Tianshu (ST25), and Shangjuxu (ST37) acupoint .Using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\]. The laser treatment will be applied to each point for 5 seconds, to deliver a total treatment dose of 4.5J/cm2 . intervention will be 3t/ week for 6 weeks in both groups.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 50
- All participants will meet diagnostic criteria (Rome IV) for IBS-C
- Their age will range from 20-35 years old
- Their body mass index (BMI) will range from >18.5kg/m2 and <29.9kg/m2
- Taking medications known to cause constipation
- Any organic diseases that might induce constipation such as colorectal cancer, metabolic disorders, multiple sclerosis, or neurological disorders
- Organic diseases of the small or large intestine such as ulcerative colitis and Crohn's disease
- A history of gastrointestinal surgery (other than appendectomy or cholecystectomy)
- Mechanical obstruction
- Serious concomitant disease of the heart, liver, or kidney or diabetes
- Pregnant or lactating women
- Severe psychiatric disorders
- Knowledgeable of acupoints and meridians that might unblind the treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Irritable Bowel Syndrome Severity Score (IBS-SSS) 6 weeks The number of complete spontaneous bowel movement (CSBMs) per week (Zhihui et al., 2022) 6 weeks
- Secondary Outcome Measures
Name Time Method IBS Quality of Life (IBS-QOL) (Andrae et al., 2013) 6 weeks Visceral Sensitivity Index (VSI) 6 weeks
Trial Locations
- Locations (1)
Egypt , Giza
🇪🇬Giza, Egypt
Egypt , Giza🇪🇬Giza, Egypt